Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 101,140 shares at $32.27 ($3.2M) on 2024-11-01, disclosed to the SEC on 2024-11-05.
Scheduled sale ($3.2M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.25 | 34,943 | $1.1M | 34.2% |
| 2 | $31.25 | 34,943 | $1.1M | 34.2% |
| 3 | $32.27 | 15,481 | $500K | 15.6% |
| 4 | $32.27 | 15,481 | $500K | 15.6% |
| 5 | $32.94 | 292 | $10K | 0.3% |
| Total | $31.57 avg | 101,140 |
| $3.2M |
| 100% |
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |